Clinical Trial

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

Study acronym: SU2C-SARC032
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2023 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2017-03-20; most recent amendment 2023-11-15.
Status change: Recruiting → Active, Not Recruiting 2023-11-15
Status change: Active, Not Recruiting → Recruiting 2018-03-16
Status change: Recruiting → Active, Not Recruiting 2018-01-26
Status change: Not Yet Recruiting → Recruiting 2017-07-19
Trial Details
NCT Number NCT03092323
Lead Sponsor Sarcoma Alliance for Research through Collaboration
Collaborators: Stand Up To Cancer, Merck Sharp & Dohme LLC
Conditions Soft Tissue Sarcoma of the Extremity
Enrollment 126 participants
Start Date 2017-07-19
Primary Completion 2025-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-18